Pavle Repovic, MD
Neurology · Seattle, WANPI 1649437211
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $768,858 of the $1,125,304 with a category attached, or 68.3%. It is spread thinly across 16 manufacturers, the largest accounting for just 21.8%. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,197 payments — averaging $940.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$245K
- TG Therapeutics, Inc.$179K
- AstraZeneca$150K
- E.r. Squibb & Sons, L.L.C.$136K
- Genentech USA, Inc.$118K
- Amgen$80K
- plus $217K from 10 others
Across 312 payments — averaging $11,763 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- Bristol Myers Squibb$584K
- E.r. Squibb & Sons, L.L.C.$535K
- Novartis$384K
- Biogen$301K
- F. Hoffmann-la Roche AG$130K
- plus $98K from 2 others
What the payments were for
- Consulting fees$229,16120%
- Speaking & faculty fees$768,85868%
- Travel & lodging$99,4009%
- Food & beverage$27,7852%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 277 | $245,289 |
| TG Therapeutics, Inc. | 176 | $178,515 |
| AstraZeneca | 167 | $149,946 |
| E.r. Squibb & Sons, L.L.C. | 119 | $136,132 |
| Genentech USA, Inc. | 124 | $118,381 |
| Amgen(2 entities) | 90 | $80,101 |
| EMD Serono, Inc. | 83 | $56,914 |
| Bristol Myers Squibb | 52 | $50,418 |
| Sanofi | 56 | $46,037 |
| Genentech, Inc. | 11 | $18,476 |
| Novartis | 26 | $17,829 |
| F. Hoffmann-la Roche AG | 6 | $9,468 |
| Banner Life Sciences, LLC | 5 | $9,318 |
| Merck Kgaa | 2 | $6,255 |
| ANI Pharmaceuticals, Inc. | 2 | $1,250 |
| Cycle Pharmaceuticals Inc | 1 | $975 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$167,073
- ZEPOSIA$140,001
- OCREVUS$107,375
- Vumerity$85,239
- UPLIZNA$78,686
- TECFIDERA$74,151
- TYSABRI$61,925
- ULTOMIRIS$49,798
- SOLIRIS$46,186
- Mavenclad$26,303
- LEMTRADA$25,649
- Enspryng$25,154
- KESIMPTA$14,078
- AUBAGIO$13,768
- Ozanimod$10,515
- Bafiertam$9,318
- Evobrutinib$6,255
- Rebif$3,451
- DISEASE STATE$3,240
- Non-Covered Product$3,000
How this compares
$1,125,304 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 41 | $233,897 |
| RebifInterferon Beta-1a/Albumin | 12 | $133,592 |
| VumerityDiroximel Fumarate | 14 | $126,990 |
| Glatiramer Acetate | 19 | $86,806 |
| FingolimodFingolimod Hcl | 29 | $56,720 |
| Dalfampridine ErDalfampridine | 87 | $41,335 |
| GlatopaGlatiramer Acetate | 16 | $29,548 |
| Dimethyl Fumarate | 91 | $25,337 |
| MyrbetriqMirabegron | 13 | $8,240 |
| Modafinil | 78 | $4,511 |
| Gabapentin | 184 | $4,173 |
| Baclofen | 206 | $3,955 |
| Carbamazepine | 35 | $1,646 |
| Pregabalin | 32 | $1,593 |
| Duloxetine Hcl | 51 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $56,914 | $133,59212 claims |
| BiogenVumerity | $245,289 | $126,99014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.
Other neurology in Seattle
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
- Leo WangSeattle$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.